Mirabegron as effective as oxybutynin for ureteral stent symptoms

Detalhes bibliográficos
Autor(a) principal: Jaworski,Paulo
Data de Publicação: 2021
Outros Autores: Mello,Gregório Fadel, Ferreira,Guilherme Monteiro, Oliveira,Maria Helena, Fraga,Rogerio de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301793
Resumo: SUMMARY OBJECTIVE: Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences. RESULTS: Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05). A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin. CONCLUSION: Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication.
id AMB-1_be19a27c7601c85115c61aafc1b8e56f
oai_identifier_str oai:scielo:S0104-42302021001301793
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling Mirabegron as effective as oxybutynin for ureteral stent symptomsUreterStentsUreteroscopyKidney calculiSUMMARY OBJECTIVE: Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences. RESULTS: Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05). A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin. CONCLUSION: Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication.Associação Médica Brasileira2021-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301793Revista da Associação Médica Brasileira v.67 n.12 2021reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20210711info:eu-repo/semantics/openAccessJaworski,PauloMello,Gregório FadelFerreira,Guilherme MonteiroOliveira,Maria HelenaFraga,Rogerio deeng2021-12-09T00:00:00Zoai:scielo:S0104-42302021001301793Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2021-12-09T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv Mirabegron as effective as oxybutynin for ureteral stent symptoms
title Mirabegron as effective as oxybutynin for ureteral stent symptoms
spellingShingle Mirabegron as effective as oxybutynin for ureteral stent symptoms
Jaworski,Paulo
Ureter
Stents
Ureteroscopy
Kidney calculi
title_short Mirabegron as effective as oxybutynin for ureteral stent symptoms
title_full Mirabegron as effective as oxybutynin for ureteral stent symptoms
title_fullStr Mirabegron as effective as oxybutynin for ureteral stent symptoms
title_full_unstemmed Mirabegron as effective as oxybutynin for ureteral stent symptoms
title_sort Mirabegron as effective as oxybutynin for ureteral stent symptoms
author Jaworski,Paulo
author_facet Jaworski,Paulo
Mello,Gregório Fadel
Ferreira,Guilherme Monteiro
Oliveira,Maria Helena
Fraga,Rogerio de
author_role author
author2 Mello,Gregório Fadel
Ferreira,Guilherme Monteiro
Oliveira,Maria Helena
Fraga,Rogerio de
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Jaworski,Paulo
Mello,Gregório Fadel
Ferreira,Guilherme Monteiro
Oliveira,Maria Helena
Fraga,Rogerio de
dc.subject.por.fl_str_mv Ureter
Stents
Ureteroscopy
Kidney calculi
topic Ureter
Stents
Ureteroscopy
Kidney calculi
description SUMMARY OBJECTIVE: Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences. RESULTS: Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05). A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin. CONCLUSION: Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301793
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301793
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1806-9282.20210711
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.67 n.12 2021
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212836961157120